Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.
Researchers say that protein levels can predict which bone marrow transplant patients are likely develop a deadly complication a week after the procedure and well before any symptoms occur.
Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.
A potential oral drug for rheumatoid arthritis (RA) may encourage women to treat their condition earlier rather than later because it is less arduous than currently available treatments. Early treatment is important because RA most often develops between the ages of 35 and 50 and is two- to three times more prevalent in women.
Researchers have uncovered a potentially new treatment approach for severe asthma, by blocking a powerful immune system chemical, present in large amounts in patients with the severe form of the disease, a small study in Thorax reveals.
Researchers have uncovered a potentially new treatment approach for severe asthma, by blocking a powerful immune system chemical, present in large amounts in patients with the severe form of the disease, a small study in Thorax reveals.
For people with long-standing rheumatoid arthritis, combined treatment with the new "biologic" drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.
More than 4.5 million adults in the United States have been diagnosed with psoriasis and 21 percent of those have moderate to severe psoriasis. This chronic condition, characterized by thick, red, scaly plaques that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.
Access to drugs whose use was approved by the UK's National Institute for Health and Clinical Excellence (NICE) three years ago is still being denied to patients with severe rheumatoid arthritis.
MPs gathered at the House of Commons on Tuesday (April 5th) as experts and patient groups urged members of parliament to lobby for improved access to treatment for patients with psoriatic arthritis, a little known and poorly understood condition in which patients experience symptoms of both psoriasis and arthritis.
Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published in the journal Arthritis Research and Therapy.
Wyeth responded to the ruling today by the U.S. Court of Appeals for the Federal Circuit in the case of Israel Bio-Engineering Project v. Amgen, Inc.
Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.
Wyeth K.K. and Takeda Pharmaceutical Company Limited (Takeda) have announced that Enbrel (etanercept) has been approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to existing therapies.
A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.
Rheumatoid arthritis patients have an approximately two-fold increased morbidity and mortality in infections compared to a population without the disease.
The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.
A new clinical study to determine how people with rheumatoid arthritis (RA) evaluate improvements in disease symptoms will be carried out by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health.
50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.
New results from TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) demonstrated that Enbrel® (etanercept) therapy allowed significantly more rheumatoid arthritis (RA) patients to achieve clinical remission at two years compared to patients treated with methotrexate alone.
The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.